80 research outputs found
Pulse Wave Velocity in Chronic Obstructive Pulmonary Disease and the Impact of Inhaled Therapy (SUMMIT): A Randomized Double-blind Clinical Trial
FEV1 is a stronger mortality predictor than FVC in mild-to-moderate patients with COPD and an increased risk for cardiovascular disease
Effect of Fluticasone Furoate and Vilanterol on Exacerbations of COPD in Patients with Moderate Airflow Obstruction
Impact of pre-enrolment medication use on clinical outcomes in SUMMIT
The impact of prior treatment on results of clinical trials in chronic obstructive pulmonary disease (COPD) has been debated. We used data from the Study to Understand Mortality and Morbidity in COPD Trial to examine the impact of prior treatment on the effects of randomised study drugs on mortality and exacerbations. We used data on 16 417 patients with moderate COPD and heightened cardiovascular risk and information on prior medications to examine the effects of fluticasone furoate (FF), vilanterol (VI) and combined FF/VI compared to placebo on moderate and severe exacerbation as well as mortality. The study was event-driven with a median study exposure of 1.8 years. This study was registered with ClinicalTrials.gov, number NCT01313676. There were no consistent associations between treatment prior to study entry and the effects of FF, VI or FF/VI on exacerbations during the study. However, patients taking inhaled corticosteroids and one or more bronchodilators prior to study entry seemed to have a better effect of active treatments than of placebo on mortality (hazard ratio for FF/VI 0.65, 95% CI 0.48–0.89). Survival in those randomised to placebo was independent of treatment prior to study enrolment. Prior treatment appears to affect treatment effects on mortality but not exacerbations in a randomised controlled trial of patients with COPD and heightened cardiovascular risk
Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial
Challenging the obesity paradox: Extreme obesity and COPD mortality in the SUMMIT Trial
Populations with COPD demonstrate higher survival in overweight and obese compared with normal weight; the “obesity paradox”. Relationships in less-severe COPD are unclear, as is the impact of cardiovascular risk, and few studies include individuals at extremes of obesity. We examined the relationship between body mass index (BMI; defined as underweight: 40 kg·m−2, suggesting that obesity may not remain protective at the extremes in this population
Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease A Systematic Review
Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial
Serum biomarkers and outcomes in patients with moderate COPD:a substudy of the randomised SUMMIT trial
- …